Search
Prohibitin-2
go.drugbank.com/bio_entities/BE0009007TargetHumansProtein with pleiotropic attributes mediated in a cell-compartment- and tissue-specific manner, which include the plasma membrane-associated cell signaling functions, mitochondrial chaperone, and transcriptional co-regulator of transcrip...
Synonyms: BAPMonopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigational[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Ondansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnCommonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. … The overall SVR12 was 88% (44/50) in treatment-naïve patients with cirrhosis [L852].
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[A176810] Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … [L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS)
Glucagon
go.drugbank.com/drugs/DB00040ApprovedInvestigational[L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631] … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
Minaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair.